Chip Davis Shares HDA’s 2025 Policy Priorities in Annual Chain Drug Review Column
In his annual “Health Care Outlook” column featured in Chain Drug Review, HDA’s President and CEO Chip Davis outlines a series of key policy priorities for healthcare distributors in 2025, as well as some challenges he expects the industry to face.
As the 119th Congress is sworn in this month and a new administration comes to Washington, Davis notes that distributors are well positioned to serve as a resource to policymakers and regulators, given they are a vital link in the healthcare supply chain:
Our 360-degree view of the healthcare supply chain enables us to respond to the most pressing issues facing the nation. Heading into 2025, our unique vantage point and expertise will help HDA shape meaningful discussions with public- and private-sector stakeholders on behalf of our most crucial priority: patients.
In the piece, Davis also discusses drug shortages, DSCSA implementation, tax issues and cybersecurity. Further, he emphasizes the importance of supporting our pharmacy partners as they face challenges across the U.S.To read the full column, click here.
More information on HDA’s policy efforts can be found here.